Johnson & Johnson (JNJ) Tuesday reported positive results from a second interim analysis of the Phase 3 CARTITUDE-4 study evaluating Carvykti compared to standard therapies for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
Results from the interim analysis showed a statistically significant and clinically meaningful improvement in overall survival (OS) for patients treated with Carvykti versus standard therapies, the company said in a statement. Further, safety data were consistent with the approved label.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.